2023-508477-87-00RecruitingPhase 1/2
PHASE IB/II CLINICAL TRIAL EVALUATING THE SAFETY AND EFFICACY OF CHEMOIMMUNOTHERAPY PLUS SHORT COURSE OF MEK INHIBITOR IN FIRST LINE OF TREATMENT OF METASTATIC NON SQUAMOUS NON SMALL CELL LUNG ADENOCARCINOMA WITH PDL1 <50%
Source: EU CTIS (euclinicaltrials.eu) · Last updated 1 Jul 2026
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 102 (estimated)
- First submitted
- 3 Nov 2023
- Start date
- 24 Jul 2024
- Lead sponsor
- Centr Georges Francois Leclerc
- Diseases
- Lung cancer
- EU CT number
- 2023-508477-87-00
What you commit to
- Study type: Interventional · Phase 1/2
- Planned participants: 102
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Centr Georges Francois Leclerc | Dijon | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.